JP2013521252A5 - - Google Patents

Download PDF

Info

Publication number
JP2013521252A5
JP2013521252A5 JP2012555403A JP2012555403A JP2013521252A5 JP 2013521252 A5 JP2013521252 A5 JP 2013521252A5 JP 2012555403 A JP2012555403 A JP 2012555403A JP 2012555403 A JP2012555403 A JP 2012555403A JP 2013521252 A5 JP2013521252 A5 JP 2013521252A5
Authority
JP
Japan
Prior art keywords
binding protein
seq
antigen binding
val
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012555403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521252A (ja
JP5922592B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/053038 external-priority patent/WO2011107480A1/en
Publication of JP2013521252A publication Critical patent/JP2013521252A/ja
Publication of JP2013521252A5 publication Critical patent/JP2013521252A5/ja
Application granted granted Critical
Publication of JP5922592B2 publication Critical patent/JP5922592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012555403A 2010-03-03 2011-03-01 血清アミロイドp成分に特異的な抗原結合タンパク質 Expired - Fee Related JP5922592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03
US61/309,957 2010-03-03
PCT/EP2011/053038 WO2011107480A1 (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016020718A Division JP6236478B2 (ja) 2010-03-03 2016-02-05 血清アミロイドp成分に特異的な抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2013521252A JP2013521252A (ja) 2013-06-10
JP2013521252A5 true JP2013521252A5 (enExample) 2014-03-20
JP5922592B2 JP5922592B2 (ja) 2016-05-24

Family

ID=43881068

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012555403A Expired - Fee Related JP5922592B2 (ja) 2010-03-03 2011-03-01 血清アミロイドp成分に特異的な抗原結合タンパク質
JP2016020718A Expired - Fee Related JP6236478B2 (ja) 2010-03-03 2016-02-05 血清アミロイドp成分に特異的な抗原結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016020718A Expired - Fee Related JP6236478B2 (ja) 2010-03-03 2016-02-05 血清アミロイドp成分に特異的な抗原結合タンパク質

Country Status (39)

Country Link
EP (2) EP2542261B1 (enExample)
JP (2) JP5922592B2 (enExample)
KR (1) KR101817265B1 (enExample)
CN (1) CN102858371B (enExample)
AR (1) AR080432A1 (enExample)
AU (1) AU2011223048C1 (enExample)
BR (1) BR112012021926A2 (enExample)
CA (1) CA2789557A1 (enExample)
CL (1) CL2012002418A1 (enExample)
CO (1) CO6602134A2 (enExample)
CR (1) CR20120491A (enExample)
CY (2) CY1118046T1 (enExample)
DK (2) DK2542261T3 (enExample)
DO (1) DOP2012000232A (enExample)
EA (1) EA026375B1 (enExample)
ES (2) ES2593454T3 (enExample)
HR (2) HRP20161096T1 (enExample)
HU (1) HUE028960T2 (enExample)
IL (2) IL221418A (enExample)
JO (1) JO3188B1 (enExample)
LT (2) LT3025729T (enExample)
MA (1) MA34135B1 (enExample)
ME (1) ME02491B (enExample)
MX (1) MX340350B (enExample)
MY (1) MY159255A (enExample)
NZ (1) NZ601763A (enExample)
PE (1) PE20130040A1 (enExample)
PH (1) PH12012501743A1 (enExample)
PL (2) PL2542261T3 (enExample)
PT (2) PT2542261T (enExample)
RS (2) RS55133B1 (enExample)
SG (2) SG183316A1 (enExample)
SI (2) SI2542261T1 (enExample)
SM (2) SMT201800633T1 (enExample)
TW (1) TWI558409B (enExample)
UA (1) UA108227C2 (enExample)
UY (1) UY33258A (enExample)
WO (1) WO2011107480A1 (enExample)
ZA (1) ZA201206529B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506876B1 (en) * 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CN1252075A (zh) 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
DE69808017T2 (de) 1997-10-31 2003-04-30 F. Hoffmann-La Roche Ag, Basel D-Prolinderivate
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
WO2004059318A2 (en) 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
CA2525302A1 (en) 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component
JP2008512353A (ja) 2004-07-21 2008-04-24 グライコフィ, インコーポレイテッド 主にGlcNAc2Man3GlcNAc2グリコフォームを含むイムノグロブリン
GB0712503D0 (en) * 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use

Similar Documents

Publication Publication Date Title
JP2013521252A5 (enExample)
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
CN105968206B (zh) 抗erbb3抗体
JP2016512551A5 (enExample)
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP2017507900A5 (enExample)
JP2020517249A5 (enExample)
JP2011506483A5 (enExample)
RU2013110874A (ru) Антитела против il-18r1 и их применения
JP2019502712A5 (enExample)
JP2017502695A5 (enExample)
JP2019530434A5 (enExample)
JP2018505177A5 (enExample)
RU2016145277A (ru) Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
JP2012504955A5 (enExample)
JP2015509947A5 (enExample)
JP2014511179A5 (enExample)
JP2011046732A5 (enExample)
JP2014503205A5 (enExample)
JP2018506277A5 (enExample)
JP2017534577A5 (enExample)
JP2015504306A5 (enExample)
JP2010504755A5 (enExample)
JP2016505546A5 (enExample)